Search the GHTC website

Global health R&D delivers for Virginia

US government investment in global health R&D has delivered

$3.3 billion
to Virginia research institutions
37,000+ new jobs
for Virginia
Virginia's top USG-funded global health R&D institutions

Virginia's top USG-funded global health R&D institutions

$239.8 million
ATCC (American Type Culture Collection)
$118.7 million
Virginia Polytechnic Institute and State University (Virginia Tech)
$66.7 million
SAIC (Science Applications International Corporation)
$65.7 million
University of Virginia
$60.4 million
US National Science Foundation (self-funding or other agency transfers)
$46.6 million
$26.3 million
Booz Allen Hamilton
$11.8 million
Luna Labs USA
$11.8 million
Northrop Grumman Corporation
$10.9 million
Eastern Virginia Medical School
$5.9 million
Virginia Commonwealth University
$4.3 million
Smithsonian Conservation Biology Institute (self-funding or other agency transfers)
$3.7 million
Gap Solutions
$2.3 million
George Mason University
$2.3 million
Luna Innovations Inc.
$1.6 million
Parabon NanoLabs Inc.
$1.2 million
University of Richmond
$1.2 million
James Madison University
$1.1 million
Phthisis Diagnostics LLC*
$1 million
Techlab Inc.
$983 thousand
CRDF Global (US Civilian Research and Development Foundation)
$670 thousand
ThunderCat Technology
$648 thousand
Undisclosed VA-based industry recipient
$565 thousand
$515 thousand
Three Wire Systems
$400 thousand
InnovaGyn Inc.
$324 thousand
Glycomantra Inc.
$300 thousand
Virongy LLC
$259 thousand
$227 thousand
Ferrum College
$188 thousand
Ceres Nanosciences Inc.
$175 thousand
NETE Solutions*
$175 thousand
Old Dominion University
$171 thousand
Calibre Systems
$156 thousand
US Systems Research and Application Corporation*
$105 thousand
DLT Solutions
$40 thousand
US Department of Defense (self-funding or other agency transfers)
$2.6 billion

Virginia's top areas of global health R&D by USG funding

Diarrheal diseases
Flioviral diseases (including Ebola, Marburg)
Neglected tropical diseases
Buruli ulcer
Helminth infections (Worms & Flukes)
Kinetoplastid diseases
Snakbite envenoming
Multi-disease/health area R&D
Arenaviral hemorrhagic fevers (including Lassa fever)
Bacterial pneumonia & meningitis
Bunyaviral diseases (including CCHF, RVF, SFTS)
Emergent non-polio enteroviruses (including EV71, D68)
Henipaviral diseases (including Nipah)
Other coronaviruses (including MERS, SARS)
Reproductive health
Salmonella infections
Global health R&D at work in Virginia

The Medicines for All Institute at Virginia Commonwealth University’s College of Engineering is working to make medicines cheaper and thus more accessible globally by driving down production costs. The team does this by reinventing the processes by which drugs are made. They consider less expensive starting materials or improved processes that ultimately translate into major cost savings. They then share this know-how with mass drug manufacturers. For the HIV drug nevirapine, for example, the program was able to reduce production costs from $200 a kilo down to $60. By making widely used drugs for high-burden global diseases cheaper, the program not only saves more lives but also increases the cost-effectiveness of US global health programs.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: FDA/Michael J. Ermarth